Consultiva Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.1K Sell
100
-100
-50% -$20.1K 0.05% 161
2026
Q2
$38K Hold
200
– – 0.09% 127
2026
Q1
$33.8K Hold
200
– – 0.1% 116
2025
Q4
$33.8K Hold
200
– – 0.09% 113
2025
Q3
$28.9K Hold
200
– – 0.08% 127
2025
Q2
$25.3K Hold
200
– – 0.08% 133
2025
Q1
$25.6K Hold
200
– – 0.09% 134
2024
Q4
$26.4K Buy
+200
New +$28.1K 0.13% 82
2023
Q3
– Sell
-60
Closed -$7.63K – 32
2023
Q2
$7.63K Hold
60
– – 0.19% 28
2023
Q1
$7.76K Hold
60
– – 0.2% 27
2022
Q4
$7.89K Buy
60
+32
+114% +$4.14K 0.21% 28
2022
Q3
$3K Hold
28
– – 0.08% 32
2022
Q2
$3K Hold
28
– – 0.08% 32
2022
Q1
$4K Hold
28
– – 0.1% 29
2021
Q4
$4K Buy
+28
New +$4.34K 0.09% 30

Other funds holding IBB

Consultiva Wealth Management's IBB Position: Q3 2026 in Review

Consultiva Wealth Management reduced its iShares Biotechnology ETF (IBB) stake by 50% in Q3 2026, selling an estimated $20.1K and leaving 100 shares worth $21.1K. The position accounts for 0.05% of the portfolio, ranked #161.

Consultiva Wealth Management first reported a position in IBB in Q4 2021 and has held it in 15 quarters since. The position peaked at $38K in Q2 2026. 1,026 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Consultiva Wealth Management held 100 shares of iShares Biotechnology ETF worth $21.1K as of Q3 2026.
  • Consultiva Wealth Management sold 100 iShares Biotechnology ETF shares in Q3 2026, an estimated $20.1K.
  • iShares Biotechnology ETF made up 0.05% of Consultiva Wealth Management's portfolio in Q3 2026, its #161 holding.
  • Consultiva Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2021 and has held it in 15 quarters since.
  • Consultiva Wealth Management's iShares Biotechnology ETF position peaked at $38K in Q2 2026.
  • 1,026 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Consultiva Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.